6-aza-nucleoside prodrugs as antiviral agents for treating virus infections
US11858956B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 17, 2021 |
| Grant date | Jan 2, 2024 |
| Priority date | — |
| Expiry date | Dec 17, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.